^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ODM-209

    i
    Other names: ODM-209, ODM 209, ODM209
    Associations

    News

    Trials
    Company:
    Orion Corp
    Drug class:
    CYP11A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    STESIDES: Safety and Pharmacokinetics of ODM-209 (clinicaltrials.gov)
    P1/2, N=38, Completed, Orion Corporation, Orion Pharma | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    ODM-209
    almost2years
    Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history. (ASCO-GU 2023)
    Two early phase trials investigating CYP11A1 inhibitors - CYPIDES (ODM208, NCT03436485) and STESIDES (ODM209, NCT03878823) - recruited mCRPC patients with and without pre-specified AR LBD mutation...Overall, 212 (78%), 202 (74%), and 240 (88%) patients had received previous abiraterone, enzalutamide, and docetaxel respectively... AR LBD mutations were detected in ctDNA in 25% of men with advanced mCRPC treated with at least one ARSI. Their incidence was associated with a longer duration of treatment with enzalutamide and a longer time from CRPC and prostate cancer diagnosis. >
    Metastases
    |
    AR (Androgen receptor) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    AR mutation • AR T878A • AR F877L • AR H875Y • AR L702H
    |
    Guardant360® CDx • FoundationOne® Liquid CDx
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • opevesostat (MK-5684) • ODM-209
    almost2years
    STESIDES: Safety and Pharmacokinetics of ODM-209 (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Orion Corporation, Orion Pharma | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    ODM-209
    almost3years
    STESIDES: Safety and Pharmacokinetics of ODM-209 (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Orion Corporation, Orion Pharma | Recruiting --> Active, not recruiting | N=256 --> 38
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    ODM-209